Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/12/23 04:19:07」(JST)

wiki en

Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia^[1] and polycythemia vera.^[2]

It has never been filed for FDA evaluation in the United States, where it is not marketed.

References

^ Kitajima K, Adachi T, Takahashi I, et al. (November 1989). "[Chemotherapy of chronic myelogenous leukemia—VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]". Gan To Kagaku Ryoho (in Japanese). 16 (11): 3573–9. PMID 2817908.
^ Nagai M, Tasaka T, Kamano H, et al. (December 1988). "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]". Gan To Kagaku Ryoho (in Japanese). 15 (12): 3267–70. PMID 3196045.

(in Japanese) Cymerin サイメリン (PDF) Mitsubishi Tanabe Pharma. October 2007.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ヒトTリンパ球好性ウイルスI型：疾患関連、診断、および治療 human t lymphotropic virus type i disease associations diagnosis and treatment
2. 成人T細胞性白血病/リンパ腫の治療および予後 treatment and prognosis of adult t cell leukemia lymphoma

English Journal

Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.

Sugimoto M1, Ito S1, Mashima K1, Umino K1, Minakata D1, Nakano H1, Yamasaki R1, Kawasaki Y1, Ashizawa M1, Yamamoto C1, Fujiwara S1, Okazuka K1, Hatano K1, Sato K1, Oh I1, Ohmine K1, Suzuki T1, Muroi K1, Kako S2, Kanda Y3,4.
Annals of hematology.Ann Hematol.2016 Sep;95(9):1513-9. doi: 10.1007/s00277-016-2740-9. Epub 2016 Jul 1.
The BEAM regimen consisting of carmustine (BCNU), etoposide, cytarabine, and melphalan (MEL) is widely used before autologous hematopoietic stem cell transplantation (auto-HSCT) for lymphoma. However, intravenous BCNU is not available in Japan, and therefore, ranimustine (MCNU) has been used instead
PMID 27365141

Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.

Roe C1, Komrokji R2, Zhang L2, Price S2, Sokol L2.
Clinical lymphoma, myeloma & leukemia.Clin Lymphoma Myeloma Leuk.2016 Aug;16 Suppl:S191-4. doi: 10.1016/j.clml.2016.02.010.
BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is aggressive mature T-cell lymphoproliferative disorder with a poor outcome.METHODS: We present 10 patients with acute and lymphomatous subtypes of ATLL treated with distinct induction regimens, including CHOP (cyclophosphamide, hydroxydaunorubicin,
PMID 27521318

Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Ogura M1,2, Ishida T3, Tsukasaki K4,5, Takahashi T6, Utsunomiya A7.
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2016 Jul;78(1):199-207. doi: 10.1007/s00280-016-3070-2. Epub 2016 Jun 11.
PURPOSE: Natural killer (NK) cells are well known to be the most important effector cells mediating antibody-dependent cellular cytotoxicity (ADCC) which is an important mechanism of action of antibody drugs. We evaluated the effects of chemotherapy on the cell number and activity of NK cells from
PMID 27289375

Japanese Journal

非ホジキンリンパ腫の治療後に急性巨核芽球性白血病として発症した治療関連急性骨髄性白血病

兒玉聖子/浅野千尋/増田道彦
東京女子医科大学雑誌 83(E2), E604-E607, 2013-03-31
… 化学療法終了後1ヶ月で再発し、ICE療法(carboplatin, ifosfamide, etoposide)を3コース施行後、Granulocyte colony-stimulating factor (G-CSF)単独投与で得た末梢血幹細胞採取に続き、MEAM 療法(ranimustine 480 mg, etoposide, cytarabine, melphalan)を前処置として自家末梢血幹細胞移植術を行った。 …
NAID 110009575072

Response to Low-dose Bortezomib in Plasma Cell Leukemia Patients with Malignant Pleural Effusion and Ascites: A Case Report and a Review of the Literature

Sekiguchi Yasunobu,Shirane Syuichi,Imai Hidenori,Sugimoto Keiji,Wakabayashi Mutsumi,Sawada Tomonori,Chigira Noriko,Ichikawa Kunimoto,Komatsu Norio,Noguchi Masaaki
Internal Medicine 51(11), 1393-1398, 2012
… A 70-year-old man was diagnosed as plasma cell leukemia and one course of ranimustine-vindesine, melphalan, and prednisolone followed by melphalan and prednisone (MP) maintained a very good partial response. …
NAID 130002062125

Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma (固形腫瘍に対する遺伝子診断の確立と予後判定の精度向上)

Yamamoto Masaaki,岩朝光利,Nonaka Masani [他]
福岡大学研究部論集 E 総合科学編 2, 107-115, 2007-03-00
NAID 40015524483

Related Pictures

Treatment protocol. The mLSG15 protocol consists of three | Download Scientific Diagram Regimen of VCAP-AMP-VECP in mLSG15. VCAP: vincristine (VCR), | Download Scientific Recent advances in the Anticancer treatment Schematic representation of the clinical trials of rituximab in Japan. | Download

★リンクテーブル★

リンク元	「ラニムスチン」「MCNU」

「ラニムスチン」

Ranimustine
Clinical data
Trade names	Cymerin
Synonyms	1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
ATC code	L01AD07 (WHO);
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name Methyl 6-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-6-deoxy-α-D-glucopyranoside;
CAS Number	58994-96-0 ;
PubChem CID	71741;
ChemSpider	64785;
UNII	RYH2T97J77;
Chemical and physical data
Formula	C10H18ClN3O7
Molar mass	327.71 g/mol
3D model (JSmol)	Interactive image;
	SMILES CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CNC(=O)N(CCCl)N=O)O)O)O ;
	InChI InChI=1S/C10H18ClN3O7/c1-20-9-8(17)7(16)6(15)5(21-9)4-12-10(18)14(13-19)3-2-11/h5-9,15-17H,2-4H2,1H3,(H,12,18)/t5-,6-,7+,8-,9+/m1/s1 ; Key:AHHFEZNOXOZZQA-ZEBDFXRSSA-N ;
(verify)